Winston Pharmaceuticals, Inc. Announces Positive Results of Phase II Clinical Trial of Dolorac(R) Nasal Solution

Published: Nov 22, 2010

VERNON HILLS, Ill.--(BUSINESS WIRE)--Winston Pharmaceuticals, Inc. (“Winston”), a specialty pharmaceutical company focused on developing and commercializing novel pain management therapies, announced the results of its Phase II study on its patented Dolorac® Nasal Solution (doxepin 0.4%) for prophylaxis of chronic migraine (“CM”) at the Lazard Capital Markets 7th Annual Healthcare Conference in New York.

Back to news